- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Pelthos Therapeutics stock initiated with Buy rating at Roth/MKM | 3 | Investing.com | ||
| PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11. | Pelthos Therapeutics GAAP EPS of -$5.30 | 1 | Seeking Alpha | ||
| 13.11. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results | 97 | GlobeNewswire (Europe) | Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1... ► Artikel lesen | |
| 13.11. | Pelthos Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer | 13 | Pharmaceutical Technology | ||
| 07.11. | Pelthos Acquires US Rights To Xepi, Secures $18 Mln Financing | - | RTTNews | ||
| 07.11. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing | 257 | GlobeNewswire (Europe) | Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMIXepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in... ► Artikel lesen | |
| 07.11. | Biofrontera Inc. announces sale of license to Xepi Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M | 150 | GlobeNewswire (Europe) | Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further... ► Artikel lesen | |
| 07.11. | EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch | 2 | Benzinga.com | ||
| 07.11. | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 | 1 | GlobeNewswire (USA) | ||
| 14.10. | Pelthos Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.10. | Pelthos rolls out Zelsuvmi with campaign aimed at moms who 'don't mess around' | 3 | FiercePharma | ||
| 09.10. | Pelthos launches Moms Against Molluscum campaign for skin infection | 1 | Investing.com | ||
| 09.10. | Pelthos startet Kampagne "Moms Against Molluscum" für neues Hautinfektionsmittel | 1 | Investing.com Deutsch | ||
| 03.09. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | Oppenheimer initiates Pelthos Therapeutics stock with Outperform rating | 3 | Investing.com | ||
| 20.08. | Ligand Q1 2025: Umsatz steigt um 46 %, strategische Fusion zu Pelthos angekündigt | 1 | Investing.com Deutsch | ||
| 20.08. | Ligand Q1 2025 slides: Revenue surges 46%, strategic Pelthos merger announced | 2 | Investing.com | ||
| 18.08. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update | 536 | GlobeNewswire (Europe) | Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,800 | -0,24 % | Kaufempfehlung und Großauftrag: Evotec, Nordex, Desert Gold | Sind über 100 % Kursgewinn bei der Nordex-Aktie noch nicht genug? Dies glauben jedenfalls Analysten. Zudem hat der Windturbinenhersteller auch noch einen Großauftrag an Land gezogen. Geht die Rally... ► Artikel lesen | |
| VALNEVA | 3,998 | +0,50 % | Valneva veröffentlicht finale Phase-2-Studiendaten für Borreliose-Impfstoff | Der französische Impfstoffhersteller Valneva hat finale Daten aus der Phase-2-Studie VLA15-221 für seinen Lyme-Borreliose-Impfstoffkandidaten VLA15 vorgelegt. Die Ergebnisse zeigen, dass die Antikörperwerte... ► Artikel lesen | |
| MAINZ BIOMED | 1,080 | -3,57 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
| AVIDITY BIOSCIENCES | 71,70 | +0,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PASITHEA THERAPEUTICS | 1,470 | +52,33 % | Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise | ||
| ARCELLX | 72,71 | -0,74 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| QIAGEN | 41,125 | -0,77 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,180 | +0,21 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 195,96 | +3,94 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| DYNE THERAPEUTICS | 21,910 | +3,50 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| HARMONY BIOSCIENCES | 35,290 | -0,76 % | Harmony Biosciences stock maintains Buy rating at H.C. Wainwright on positive study results | ||
| ARCUTIS BIOTHERAPEUTICS | 30,650 | -1,00 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| RECURSION PHARMACEUTICALS | 4,630 | +4,99 % | Recursion Pharmaceuticals registriert Aktienpaket für Wiederverkauf durch Tempus AI | ||
| COGENT BIOSCIENCES | 40,250 | -0,35 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| DAY ONE BIOPHARMACEUTICALS | 9,490 | +0,85 % | Day One Biopharmaceuticals stock maintains Buy rating at H.C. Wainwright |
Das Unternehmen PELTHOS THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 28,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PELTHOS THERAPEUTICS INC finden Sie auf Wallstreet Online.